GenSight Biologics S.A. (SIGHT.PA)
EUR 0.29
(-3.52%)
EUR 0.29
(-3.52%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 18.42 Million EUR | 45.71% |
| 2022 | 12.64 Million EUR | 0.64% |
| 2021 | 12.56 Million EUR | -13.04% |
| 2020 | 14.45 Million EUR | 81.83% |
| 2019 | 7.94 Million EUR | 130.95% |
| 2018 | 3.44 Million EUR | 13.45% |
| 2017 | 3.03 Million EUR | 3.78% |
| 2016 | 2.92 Million EUR | 369.7% |
| 2015 | 622.19 Thousand EUR | -1.6% |
| 2014 | 632.33 Thousand EUR | 0.0% |
| 2013 | - EUR | 0.0% |
| 2012 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 21.24 Million EUR | 6.78% |
| 2024 Q1 | 21.24 Million EUR | 15.26% |
| 2023 Q4 | 18.42 Million EUR | -19.03% |
| 2023 FY | 18.42 Million EUR | 45.71% |
| 2023 Q3 | 22.76 Million EUR | 41.9% |
| 2023 Q1 | 20.83 Million EUR | 64.74% |
| 2023 Q2 | 16.04 Million EUR | -23.01% |
| 2022 Q2 | 11.01 Million EUR | -27.54% |
| 2022 Q3 | 16.96 Million EUR | 54.02% |
| 2022 Q1 | 15.2 Million EUR | 20.98% |
| 2022 Q4 | 12.64 Million EUR | -25.46% |
| 2022 FY | 12.64 Million EUR | 0.64% |
| 2021 Q1 | 18.24 Million EUR | 26.28% |
| 2021 Q3 | 16.77 Million EUR | 19.53% |
| 2021 Q2 | 14.03 Million EUR | -23.11% |
| 2021 FY | 12.56 Million EUR | -13.04% |
| 2021 Q4 | 12.56 Million EUR | -25.07% |
| 2020 Q3 | 18.56 Million EUR | 51.03% |
| 2020 Q2 | 12.29 Million EUR | -20.39% |
| 2020 FY | 14.45 Million EUR | 81.83% |
| 2020 Q1 | 15.44 Million EUR | 94.35% |
| 2020 Q4 | 14.45 Million EUR | -22.18% |
| 2019 Q3 | 10.26 Million EUR | 151.6% |
| 2019 Q4 | 7.94 Million EUR | -22.6% |
| 2019 FY | 7.94 Million EUR | 130.95% |
| 2019 Q1 | 6.88 Million EUR | 100.03% |
| 2019 Q2 | 4.08 Million EUR | -40.71% |
| 2018 Q3 | 3.44 Million EUR | 1.0% |
| 2018 Q4 | 3.44 Million EUR | 0.0% |
| 2018 FY | 3.44 Million EUR | 13.45% |
| 2018 Q1 | 3.4 Million EUR | 12.33% |
| 2018 Q2 | 3.4 Million EUR | 0.0% |
| 2017 Q3 | 3.03 Million EUR | 12.29% |
| 2017 Q4 | 3.03 Million EUR | 0.0% |
| 2017 Q1 | 2.7 Million EUR | -7.58% |
| 2017 Q2 | 2.7 Million EUR | 0.0% |
| 2017 FY | 3.03 Million EUR | 3.78% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 2.92 Million EUR | 369.7% |
| 2016 Q4 | 2.92 Million EUR | 0.02% |
| 2016 Q3 | 2.92 Million EUR | 0.0% |
| 2015 Q3 | 622.19 Thousand EUR | -2.09% |
| 2015 Q1 | 635.49 Thousand EUR | 0.5% |
| 2015 FY | 622.19 Thousand EUR | -1.6% |
| 2015 Q2 | 635.49 Thousand EUR | 0.0% |
| 2015 Q4 | 622.19 Thousand EUR | 0.0% |
| 2014 FY | 632.33 Thousand EUR | 0.0% |
| 2014 Q4 | 632.33 Thousand EUR | 0.0% |
| 2014 Q3 | 632.33 Thousand EUR | 0.0% |
| 2014 Q1 | - EUR | 0.0% |
| 2013 FY | - EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -443.599% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 66.775% |
| Adocia SA | 13.08 Million EUR | -40.801% |
| Aelis Farma SA | 4.03 Million EUR | -356.365% |
| Biophytis S.A. | 8.27 Million EUR | -122.83% |
| Advicenne S.A. | 17.42 Million EUR | -5.756% |
| genOway Société anonyme | 7.23 Million EUR | -154.763% |
| IntegraGen SA | 1.12 Million EUR | -1538.43% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1435.667% |
| Neovacs S.A. | 650 Thousand EUR | -2735.077% |
| NFL Biosciences SA | 62.17 Thousand EUR | -29539.399% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -322.999% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -578.288% |
| Sensorion SA | 2.86 Million EUR | -542.362% |
| Theranexus Société Anonyme | 3.64 Million EUR | -405.844% |
| TME Pharma N.V. | 1.16 Million EUR | -1480.446% |
| Valbiotis SA | 6.87 Million EUR | -167.927% |
| TheraVet SA | 1.15 Million EUR | -1488.803% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -104.801% |
| argenx SE | 18.1 Million EUR | -1.782% |
| BioSenic S.A. | 28.16 Million EUR | 34.562% |
| Celyad Oncology SA | 902 Thousand EUR | -1943.016% |
| DBV Technologies S.A. | 13.01 Million USD | -41.551% |
| Galapagos NV | 9.59 Million EUR | -92.038% |
| Genfit S.A. | 70.17 Million EUR | 73.741% |
| GeNeuro SA | 7.73 Million EUR | -138.156% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -248.092% |
| Innate Pharma S.A. | 39.89 Million EUR | 53.806% |
| Inventiva S.A. | 37.4 Million EUR | 50.736% |
| MaaT Pharma SA | 14.07 Million EUR | -30.927% |
| MedinCell S.A. | 58.96 Million EUR | 68.745% |
| Nanobiotix S.A. | 50.56 Million EUR | 63.556% |
| Onward Medical N.V. | 16.87 Million EUR | -9.209% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -34.636% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 59.765% |
| Oxurion NV | 12.33 Million EUR | -49.408% |
| Pharming Group N.V. | 155.29 Million EUR | 88.133% |
| Poxel S.A. | 46.9 Million EUR | 60.708% |
| Transgene SA | 1.25 Million EUR | -1366.03% |
| Financière de Tubize SA | 79.2 Million EUR | 76.732% |
| UCB SA | 3.03 Billion EUR | 99.393% |
| Valneva SE | 208.81 Million EUR | 91.175% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -48394.737% |